18F-FDG PET/MRI for Staging and Interim Response Assessment in Pediatric and Adolescent Hodgkin Lymphoma : A Prospective Study with 18F-FDG PET/CT as the Reference Standard
© 2021 by the Society of Nuclear Medicine and Molecular Imaging..
Treatment regimens for pediatric Hodgkin lymphoma (HL) depend on accurate staging and treatment response assessment, based on accurate disease distribution and metabolic activity depiction. With the aim of radiation dose reduction, we compared the diagnostic performance of 18F-FDG PET/MRI with a 18F-FDG PET/CT reference standard for staging and response assessment. Methods: Twenty-four patients (mean age, 15.4 y; range, 8-19.5 y) with histologically proven HL were prospectively and consecutively recruited in 2015 and 2016, undergoing both 18F-FDG PET/CT and 18F-FDG PET/MRI at initial staging (n = 24) and at response assessment (n = 21). The diagnostic accuracy of 18F-FDG PET/MRI for both nodal and extranodal disease was compared with that of 18F-FDG PET/CT, which was considered the reference standard. Discrepancies were retrospectively classified as perceptual or technical errors, and 18F-FDG PET/MRI and 18F-FDG PET/CT were corrected by removing perceptual error. Agreement with Ann Arbor staging and Deauville grading was also assessed. Results: For nodal and extranodal sites combined, corrected staging 18F-FDG PET/MRI sensitivity was 100% (95% CI, 96.7%-100%) and specificity was 99.5% (95% CI, 98.3%-99.9%). Corrected response-assessment 18F-FDG PET/MRI sensitivity was 83.3% (95% CI, 36.5%-99.1%) and specificity was 100% (95% CI, 99.2%-100%). Modified Ann Arbor staging agreement between 18F-FDG PET/CT and 18F-FDG PET/MRI was perfect (κ = 1.0, P = 0.000). Deauville grading agreement between 18F-FDG PET/MRI and 18F-FDG PET/CT was excellent (κ = 0.835, P = 0.000). Conclusion:18F-FDG PET/MRI is a promising alternative to 18F-FDG PET/CT for staging and response assessment in children with HL.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:62 |
|---|---|
| Enthalten in: |
Journal of nuclear medicine : official publication, Society of Nuclear Medicine - 62(2021), 11 vom: 10. Nov., Seite 1524-1530 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Verhagen, Martijn V [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
0Z5B2CJX4D |
|---|
| Anmerkungen: |
Date Completed 05.01.2022 Date Revised 03.05.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.2967/jnumed.120.260059 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM321671422 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM321671422 | ||
| 003 | DE-627 | ||
| 005 | 20231225180357.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2967/jnumed.120.260059 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1072.xml |
| 035 | |a (DE-627)NLM321671422 | ||
| 035 | |a (NLM)33608429 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Verhagen, Martijn V |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a 18F-FDG PET/MRI for Staging and Interim Response Assessment in Pediatric and Adolescent Hodgkin Lymphoma |b A Prospective Study with 18F-FDG PET/CT as the Reference Standard |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 05.01.2022 | ||
| 500 | |a Date Revised 03.05.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2021 by the Society of Nuclear Medicine and Molecular Imaging. | ||
| 520 | |a Treatment regimens for pediatric Hodgkin lymphoma (HL) depend on accurate staging and treatment response assessment, based on accurate disease distribution and metabolic activity depiction. With the aim of radiation dose reduction, we compared the diagnostic performance of 18F-FDG PET/MRI with a 18F-FDG PET/CT reference standard for staging and response assessment. Methods: Twenty-four patients (mean age, 15.4 y; range, 8-19.5 y) with histologically proven HL were prospectively and consecutively recruited in 2015 and 2016, undergoing both 18F-FDG PET/CT and 18F-FDG PET/MRI at initial staging (n = 24) and at response assessment (n = 21). The diagnostic accuracy of 18F-FDG PET/MRI for both nodal and extranodal disease was compared with that of 18F-FDG PET/CT, which was considered the reference standard. Discrepancies were retrospectively classified as perceptual or technical errors, and 18F-FDG PET/MRI and 18F-FDG PET/CT were corrected by removing perceptual error. Agreement with Ann Arbor staging and Deauville grading was also assessed. Results: For nodal and extranodal sites combined, corrected staging 18F-FDG PET/MRI sensitivity was 100% (95% CI, 96.7%-100%) and specificity was 99.5% (95% CI, 98.3%-99.9%). Corrected response-assessment 18F-FDG PET/MRI sensitivity was 83.3% (95% CI, 36.5%-99.1%) and specificity was 100% (95% CI, 99.2%-100%). Modified Ann Arbor staging agreement between 18F-FDG PET/CT and 18F-FDG PET/MRI was perfect (κ = 1.0, P = 0.000). Deauville grading agreement between 18F-FDG PET/MRI and 18F-FDG PET/CT was excellent (κ = 0.835, P = 0.000). Conclusion:18F-FDG PET/MRI is a promising alternative to 18F-FDG PET/CT for staging and response assessment in children with HL | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Hodgkin lymphoma | |
| 650 | 4 | |a PET/CT | |
| 650 | 4 | |a PET/MRI | |
| 650 | 4 | |a pediatric | |
| 650 | 4 | |a staging | |
| 650 | 7 | |a Fluorodeoxyglucose F18 |2 NLM | |
| 650 | 7 | |a 0Z5B2CJX4D |2 NLM | |
| 700 | 1 | |a Menezes, Leon J |e verfasserin |4 aut | |
| 700 | 1 | |a Neriman, Deena |e verfasserin |4 aut | |
| 700 | 1 | |a Watson, Tom A |e verfasserin |4 aut | |
| 700 | 1 | |a Punwani, Shonit |e verfasserin |4 aut | |
| 700 | 1 | |a Taylor, Stuart A |e verfasserin |4 aut | |
| 700 | 1 | |a Shankar, Ananth |e verfasserin |4 aut | |
| 700 | 1 | |a Daw, Stephen |e verfasserin |4 aut | |
| 700 | 1 | |a Humphries, Paul D |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of nuclear medicine : official publication, Society of Nuclear Medicine |d 1960 |g 62(2021), 11 vom: 10. Nov., Seite 1524-1530 |w (DE-627)NLM000042072 |x 1535-5667 |7 nnns |
| 773 | 1 | 8 | |g volume:62 |g year:2021 |g number:11 |g day:10 |g month:11 |g pages:1524-1530 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2967/jnumed.120.260059 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 62 |j 2021 |e 11 |b 10 |c 11 |h 1524-1530 | ||